Immunic's Vidofludimus Calcium Achieves Major Milestones in Reducing Disability in MS Patients Immunic, Inc. announces promising results for Vidofludimus Calcium in reducing disability in Primary Progressive MS patients by 30%.

Immunic's Vidofludimus Calcium Achieves Major Milestones in Reducing Disability in MS Patients #United_States #New_York #Immunic #Vidofludimus #MS_Therapy